Logo image
In adults at high CV risk and without previous MI or stroke, evolocumab reduced major adverse CV event composites at a median 4.6 y
Journal article   Peer reviewed

In adults at high CV risk and without previous MI or stroke, evolocumab reduced major adverse CV event composites at a median 4.6 y

Anthony Donato and ACP Journal Club Editorial Team at McMaster University
Annals of internal medicine
03 Mar 2026
PMID: 41771125

Abstract

GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].

Details

Logo image